Skip to main content

Advertisement

SpringerLink
Log in

Calcium Channel Blockers Co-prescribed with Loop Diuretics: A Potential Marker of Poor Prescribing?

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Prescribing cascades are where a drug adverse reaction is wrongly attributed to the emergence of a new condition, which leads to further drug prescribing. This promotes polypharmacy, adverse drug reactions and therapeutic burden. An example of a prescribing cascade is the co-prescribing of loop diuretics to treat the peripheral oedema caused by calcium channel blocker (CCB) drugs. Although well recognised, this is still a combination of medications taken by millions of people worldwide. CCBs have no prognostic benefit in heart failure and have an absolute risk increase for oedema of around 8–18% (number needed to harm 6–13). In the treatment of hypertension, they also increase the risk of oedema and a new diagnosis of heart failure without having any major advantages over alternative drugs. The best way to manage the oedema caused by CCBs is to switch to an alternative medication. Only where this is not possible or fails to achieve therapeutic goals would the CCB–loop diuretic combination appear to be justified. In many cases, therapeutic practice could be improved by targeting people on CCB–loop diuretic combinations for medication review. This could improve quality of life and reduce polypharmacy, adverse drug reactions, therapeutic burden and financial costs for millions of people worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kelly J, Chambers J. Inappropriate use of loop diuretics in elderly patients. Age Ageing. 2000;29:489–93.

    Article  CAS  Google Scholar 

  2. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096–9.

    Article  CAS  Google Scholar 

  3. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation: making it safe and sound. The King’s Fund 2013. http://www.kingsfund.org.uk/publications/polypharmacy-and-medicines-optimisation. Accessed 9 July 2019.

  4. Nguyen PV, Spinelli C. Prescribing cascade in an elderly woman. CPJ/RPC. 2016;149:122–4.

    PubMed  Google Scholar 

  5. Berry SD, Mittleman MA, Zhang Y, et al. New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home. Pharmacoepidemiol Drug Saf. 2012;21:560–3.

    Article  CAS  Google Scholar 

  6. Xiao F, Qu X, Zhai Z, et al. Association between loop diuretic use and fracture risk. Osteoporos Int. 2015;26:775–84.

    Article  CAS  Google Scholar 

  7. Ekundayo OJ, Markland A, Lefante C, et al. Association of diuretic use and overactive bladder syndrome in older adults: a propensity score analysis. Arch Gerontol Geriatr. 2009;49:64–8.

    Article  Google Scholar 

  8. Vouri SM, van Tuyl JS, Olsen MA, et al. An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade. J Am Pharm Assoc. 2018;58:534–9.

    Article  Google Scholar 

  9. Rodriguez-Cillero C, Menu D, d’Athis P. Potentially inappropriate use of furosemide in a very elderly population: an observational study. Int J Clin Pract. 2017;71:e12975.

    Article  Google Scholar 

  10. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52–60.

    Article  CAS  Google Scholar 

  11. Sica DA. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens. 2003;5:291–7.

    Article  Google Scholar 

  12. Chrysan SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens. 2008;10:716–22.

    Article  Google Scholar 

  13. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hyperten. 2001;14:978–9.

    Article  CAS  Google Scholar 

  14. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15:932–40.

    Article  CAS  Google Scholar 

  15. Handler J. Managing calcium channel blocker-related peripheral edema. J Clin Hypertens. 2004;6:400–2.

    Article  Google Scholar 

  16. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ace inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens. 2001;14:963–8.

    Article  CAS  Google Scholar 

  17. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23:503–11.

    Article  Google Scholar 

  18. Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine⁄valsartan 5⁄160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009;63:217–25.

    Article  CAS  Google Scholar 

  19. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54:32–9.

    Article  CAS  Google Scholar 

  20. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006–14.

    Article  Google Scholar 

  21. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. NEJM. 1996;335:1107–14.

    Article  CAS  Google Scholar 

  22. Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). J Am Coll Cardiol HF. 2013;1:308–14.

    Google Scholar 

  23. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation. 1997;96:856–63.

    Article  CAS  Google Scholar 

  24. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J. 1995;73:428–33.

    Article  CAS  Google Scholar 

  25. Patel K, Fonarow GC, Ahmed M, et al. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7:945–52.

    Article  CAS  Google Scholar 

  26. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Clinical guideline 127; 2011. http://www.nice.org.uk/guidance/cg127.

  27. Handler J. Resistant hypertension responding to change from furosemide to thiazide: understanding calcium channel blocker-related edema. J Clin Hypertens. 2010;12:949–52.

    Article  Google Scholar 

  28. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther. 2010;8:793–802.

    Article  CAS  Google Scholar 

  29. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–6.

    Article  CAS  Google Scholar 

  30. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–72.

    Article  CAS  Google Scholar 

  31. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.

    Article  Google Scholar 

  32. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.

    Article  Google Scholar 

  33. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.

    Article  Google Scholar 

  34. National Institue for Health and Care Excellence. Stable angina: management. Clinical guideline 126, 2011. http://nice.org.uk/guidance/cg126.

  35. Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74.

    Article  Google Scholar 

  36. O’Mahony D, Gallagher P, Ryan C, et al. STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med. 2010;1:45–51.

    Article  Google Scholar 

  37. Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017;389:1778–80.

    Article  Google Scholar 

  38. Dalton K, O’Brien G, O’Mahony D, et al. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing. 2018;47:670–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northumbria Healthcare, North Shields, Tyne and Wear, UK

    Henry J. Woodford

Authors
  1. Henry J. Woodford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry J. Woodford.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this article.

Conflict of interest

The authors declare that they have no competing interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woodford, H.J. Calcium Channel Blockers Co-prescribed with Loop Diuretics: A Potential Marker of Poor Prescribing?. Drugs Aging 37, 77–81 (2020). https://doi.org/10.1007/s40266-019-00730-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-019-00730-4

Search

Navigation